HP661 |
| Catalog No.GC91057 |
Un inhibiteur de la complexe I mitochondriale.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
HP661 is an inhibitor of mitochondrial complex I, also known as NADH dedrogenase.1 It is selective for complex I, inhibiting it by 77.6%, over complex III, which it inhibits by 28.1%, and complexes II and IV, which it does not inhibit, at 1 µM. HP661 selectively reduces viability of the human lung cancer cells H460, NCI H441, and trametinib-resistant A549 cells (IC50s = 10.6, 29.7, and 15.1 nM, respectively), which all have high levels of oxidative phosphorylation, over NCI H358 human lung cancer cells (IC50 = >10,000 nM), which have low levels of oxidative phosphorylation, and non-cancerous human pancreatic normal epithelial (HPNE) and MRC-5 human fetal lung fibroblast cells (IC50s = >10,000 nM for both). HP661 reduces tumor volume in an H460 mouse xenograft model when administered at a dose of 30 mg/kg twice per day and has an additive effect on trametinib-induced reduction of tumor growth.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *